PMC/PubMed Indexed Articles
Indexed In
- Open J Gate
- Genamics JournalSeek
- SafetyLit
- RefSeek
- Hamdard University
- EBSCO A-Z
- OCLC- WorldCat
- Publons
- Geneva Foundation for Medical Education and Research
- Euro Pub
- Google Scholar
Useful Links
Share This Page
Journal Flyer
Open Access Journals
- Agri and Aquaculture
- Biochemistry
- Bioinformatics & Systems Biology
- Business & Management
- Chemistry
- Clinical Sciences
- Engineering
- Food & Nutrition
- General Science
- Genetics & Molecular Biology
- Immunology & Microbiology
- Medical Sciences
- Neuroscience & Psychology
- Nursing & Health Care
- Pharmaceutical Sciences
Nicolas Maréchal
Nicolas Maréchal
Vrije Universiteit Brussel (VUB),
UZ Brussel, Laarbeeklaan 101, 1090 Brussels
Belgium
Publications
-
Case Report
Case Report: Treatment Resistant Ipilimumab Related Colitis in an Elderly Metastatic Melanoma Patient
Author(s): Nicolas Maréchal*, Sofie Wilgenhof, Bart Neyns, Veerle Morlion, Daniel Urbain, Tony Mets and Ingo Beyer Nicolas Maréchal*, Sofie Wilgenhof, Bart Neyns, Veerle Morlion, Daniel Urbain, Tony Mets and Ingo Beyer
Background: Ipilimumab is a fully humanized monoclonal antibody against cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4). In 2010, ipilimumab became the first systemic therapy to improve the overall survival of patients with advanced melanoma in two randomized phase III clinical trials. Related to its immune-cell activating mode of action, ipilimumab therapy is associated with a spectrum of immune-related adverse events (irAEs), most commonly located at the skin and gastrointestinal tract. IrAEs are managed by withdrawal of ipilimumab and early administration of high-dose corticosteroids. Ipilimumab-related colitis, refractory to corticotherapy has been reported to respond readily to treatment with the anti-tumor-necrosis-factor monoclonal antibody infliximab. Case report: We describe a case of severe ipilimumab-related colitis in an elderl.. View More»
DOI: 10.4172/2167-7182.1000461